ABOS - NASDAQ
Acumen Pharmaceuticals, Inc.
$2.37
+2.6%Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
At a Glance
Live SnapshotAcumen Pharmaceuticals, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Acumen Pharmaceuticals, Inc. Cash Flow Statement
ABOS • NASDAQ
| Acumen Pharmaceuticals, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||
-121.3M | -102.3M | -52.4M | -42.9M | -100.6M | -7.3M | -7.9M | |
-751K | 178K | 184K | 169K | 4K | 0.0 | 0.0 | |
9.9M | 9.6M | 6.1M | 3.1M | 922K | 154K | 174K | |
1.8M | -5.4M | -888K | 487K | 81.4M | -586K | 147K | |
-5.1M | 11.7M | 3.9M | 4M | 298K | 307K | 768K | |
-115.5M | -86.2M | -43.1M | -35.2M | -18M | -7.5M | -6.8M | |
INVESTING ACTIVITIES | |||||||
-88K | -16K | -21K | -161K | -40K | (0.0) | (0.0) | |
(0.0) | (0.0) | (3K) | -39.3K | (0.0) | (0.0) | (0.0) | |
-38.1M | -170.7M | -250.6M | -41.5M | -104.1M | (0.0) | (0.0) | |
172.1M | 218.8M | 79M | 80.9M | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 39.3K | 0.0 | 0.0 | 0.0 | |
(133.9M) | (48M) | -171.7M | (39.2M) | -104.1M | (0.0) | (0.0) | |
FINANCING ACTIVITIES | |||||||
-34K | 7.9M | 121.9M | 3.8M | 168.6M | 0.0 | 0.0 | |
0.0 | -739K | 30M | 0.0 | 0.0 | 0.0 | 0.0 | |
-73K | -41K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | -230K | -151K | 115K | 1.9M | 0.0 | 7K | |
-34K | 6.9M | 151.8M | 3.9M | 200.5M | 44.7M | 6.2M | |
CASH FLOW SUMMARY | |||||||
18.4M | -31.3M | -63M | 7.9M | 78.4M | 37.2M | -579K | |
35.9M | 67.1M | 130.1M | 122.2M | 43.8M | 6.6M | 7.1M | |
54.2M | 35.9M | 67.1M | 130.1M | 122.2M | 43.8M | 6.6M | |
-115.6M | -86.2M | -43.1M | -35.3M | -18M | -7.5M | -6.8M |
SEC Filings
ABOS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 03, 2026 | June 03, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 23, 2026 | December 31, 2025 | 2025 | |
S-3 S-3 N/A | March 26, 2026 | March 26, 2026 | ||
10-K 10-K 2025 FY FY | March 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 26, 2026 | March 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 16, 2026 | March 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your ABOS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.